San Diego-based Viking Therapeutics marked alone as a significant competitor within the weight loss drug current market in February soon after revealing promising knowledge from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the comp